» Articles » PMID: 24152954

Reduction of Fibrosis in Dibutyltin Dichloride-induced Chronic Pancreatitis Using Rat Umbilical Mesenchymal Stem Cells from Wharton's Jelly

Overview
Journal Pancreas
Specialty Gastroenterology
Date 2013 Oct 25
PMID 24152954
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The objective of this study was to investigate the effects of rat umbilical cord mesenchymal stem cells (UCMSCs) from Wharton's jelly on dibutyltin dichloride (DBTC)-induced chronic pancreatitis (CP) and subsequent pancreatic fibrosis in rats.

Methods: A rat model of CP induced by DBTC was used. Male Sprague-Dawley rats were randomly divided into 4 groups: the control, DBTC, DBTC + UCMSCs, and control + UCMSC groups. Umbilical cord mesenchymal stem cells were administered intravenously on day 5 after the administration of DBTC. On days 14 and 28, the rats were evaluated morphologically and biochemically. The expression levels of inflammatory cytokines and chemokines in the pancreatic tissues of different groups were evaluated using quantitative real-time polymerase chain reaction. The activation of pancreatic stellate cells was estimated by immunochemistry and Western blot analysis of α-smooth muscle actin.

Results: Umbilical cord mesenchymal stem cells were detected in inflamed pancreatic tissues. Umbilical cord mesenchymal stem cell treatment improved the histological scores and alleviated the fibrosis of pancreas samples, The expression of cytokines in the DBTC + UCMSC group was significantly lower than that in the DBTC group. Also, pancreatic stellate cell activation was inhibited by UCMSC treatment.

Conclusions: Xenogeneic transplantation of UCMSCs is a novel approach for the treatment of CP and subsequent fibrosis. Umbilical cord mesenchymal stem cells may be a promising therapeutic intervention for human CP in the future.

Citing Articles

High-mobility group box 1 fragment ameliorates chronic pancreatitis induced by caerulein in mice.

Hokkoku D, Sasaki K, Kobayashi S, Shimbo T, Kitayama T, Yamazaki S J Gastroenterol. 2024; 59(8):744-757.

PMID: 38727823 DOI: 10.1007/s00535-024-02112-z.


Innovative preconditioning strategies for improving the therapeutic efficacy of extracellular vesicles derived from mesenchymal stem cells in gastrointestinal diseases.

Didamoony M, Soubh A, Atwa A, Ahmed L Inflammopharmacology. 2023; 31(6):2973-2993.

PMID: 37874430 PMC: 10692273. DOI: 10.1007/s10787-023-01350-6.


The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis.

Li B, Liu X, Mao T, Zheng T, Zhang P, Zhang Q Front Oncol. 2022; 12:1050274.

PMID: 36505827 PMC: 9730810. DOI: 10.3389/fonc.2022.1050274.


Mesenchymal stem cell treatment for enteric neuropathy in the Winnie mouse model of spontaneous chronic colitis.

Robinson A, Stavely R, Miller S, Eri R, Nurgali K Cell Tissue Res. 2022; 389(1):41-70.

PMID: 35536444 DOI: 10.1007/s00441-022-03633-w.


A Novel Cellular Therapy to Treat Pancreatic Pain in Experimental Chronic Pancreatitis Using Human Alpha-1 Antitrypsin Overexpressing Mesenchymal Stromal Cells.

Chow R, Nguyen K, Gou W, Green E, Morgan K, Lancaster W Biomedicines. 2021; 9(11).

PMID: 34829924 PMC: 8615652. DOI: 10.3390/biomedicines9111695.